Total body weight is embedded in drug dosing because it is inexpensive, reproducible, and immediately available. Its convenience, however, can obscure the fact that a kilogram does not identify the biological quantity responsible for drug distribution or clearance. Adipose tissue, lean tissue, extracellular fluid, plasma volume, kidney function, hepatic metabolic capacity, transporter activity, and protein binding can change independently, sometimes in opposite directions. Consequently, patients with similar body weight may have markedly different pharmacokinetic states, whereas large changes in body weight may occur with little change in a drug-relevant elimination pathway. Obesity illustrates the problem but does not define it. Increased adiposity changes distribution differently for hydrophilic and lipophilic compounds, while obesity-related differences in kidney function, hepatic blood flow, transporter activity, or comorbidity may modify clearance independently of fat mass. Sarcopenia introduces a different discordance: low muscle mass may reduce the physiological relevance of total weight and simultaneously distort creatinine-based estimates of kidney function. Edema, ascites, and fluid resuscitation may increase measured weight while expanding extracellular distribution volume without increasing metabolic or excretory capacity. During aging, critical illness, weight loss, or progressive organ disease, these determinants also evolve asynchronously. The clinically useful question is therefore not which single descriptor should replace total body weight. It is which physiological dimension is mechanistically connected to the disposition of the drug being dosed. Total weight remains informative for some medicines, but its value is conditional on drug properties, distribution space, tissue transport, binding, and elimination pathway. Pharmacological size should therefore be interpreted as a drug- and process-specific quantity rather than a universal anthropometric scalar.
